SQSTM1 mutations–bridging Paget disease of bone and ALS/FTLD

SL Rea, V Majcher, MS Searle, R Layfield - Experimental cell research, 2014 - Elsevier
SL Rea, V Majcher, MS Searle, R Layfield
Experimental cell research, 2014Elsevier
Paget disease of bone (PDB) is a skeletal disorder common in Western Europe but
extremely rare in the Indian subcontinent and Far East. The condition has a strong genetic
element with mutations affecting the SQSTM1 gene, encoding the p62 protein, frequently
identified. Recently SQSTM1 mutations have also been reported in a small number of
patients with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration
(FTLD), neurodegenerative disorders in which significant coexistence with PDB has not …
Abstract
Paget disease of bone (PDB) is a skeletal disorder common in Western Europe but extremely rare in the Indian subcontinent and Far East. The condition has a strong genetic element with mutations affecting the SQSTM1 gene, encoding the p62 protein, frequently identified. Recently SQSTM1 mutations have also been reported in a small number of patients with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), neurodegenerative disorders in which significant coexistence with PDB has not been previously recognized. Although several SQSTM1 mutations are common to both ALS/FTLD and PDB, many are ALS/FTLD-specific. The p62 protein regulates various cellular processes including NF-κB signaling and autophagy pathways. Here we consider how knowledge of the impact of PDB-associated SQSTM1 mutations (several of which are now known to be relevant for ALS/FTLD) on these pathways, as well as the locations of the mutations within the p62 primary sequence, may provide new insights into ALS/FTLD disease mechanisms.
Elsevier